Cure CMT is partnering with Tamarack Habilitation Technologies to expand access to advanced orthotic devices…
Andrea Lobo
Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo
Mutations in the GJB1 gene affecting transmembrane, or cell membrane-spanning, regions of the connexin-32 protein are associated with more severe…
An orthopedic surgeon at the University of Iowa has been awarded the 2025 Inherited Neuropathy Fellowship to advance her research…
The Charcot-Marie-Tooth Association (CMTA) is funding two research projects to accelerate the development of genetic therapies for less common…
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Encell’s EN001, an investigational stem cell…
The use of 3D-printed, customized ankle braces may improve balance and reduce foot pain in people with Charcot-Marie-Tooth (CMT)…
The CMT Research Foundation (CMTRF) has raised more than its $10 million goal for the Endgame campaign to…
Cochlear implants are a safe and reliable way to improve hearing, speech, and quality of life for people with…
The CMT Research Foundation (CMTRF) has invested in a project at Vanderbilt University School of Medicine Basic Sciences for…
Oryzon Genomics has chosen ORY-4001, a selective histone deacetylase 6 (HDAC6) inhibitor, for clinical development as a potential treatment…